Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.59 |
| ▸ | SELP | P16109 | 8/20 | 0.53 |
| ▸ | MAG | P20916 | 5/20 | 0.51 |
| ▸ | SELL | P14151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29693395 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL29361939 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30739463 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30654239 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL20455686 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL20455685 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30653186 | 1.00 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30913852 | 0.99 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL16449748 | 0.99 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL | |
| SCHEMBL30654197 | 0.99 | SIGLEC7 (0.59) | SIGLEC7SELPMAGSELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1981 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727571-A2 | ACTIVATION OF T-CELLS WITH MUTANT G-CSFR | Interius Biotherapeutics, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4442277-B1 | STABILIZED ANTIBODY-CONTAINING LIQUID FORMULATIONS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-04-22 | — | — | EP | claimed |
| EP-4725503-A2 | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | University Of Southern California (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724464-A1 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Interius Biotherapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724112-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOLOGICAL DISORDERS | Interius Biotherapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260098074-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2026-04-09 | — | — | US | claimed |
| EP-4720312-A2 | GENE EDITING COMPOSITIONS OF POLYPEPTIDES AND NUCLEIC ACIDS, AND USES THEREOF | Interius Biotherapeutics, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260071235-A1 | METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO | ANGELES THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | claimed |
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | ANGELES THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4687964-A2 | METHOD OF VACCINATING FOR CANCER AND DEVICE AND KIT THEREFOR | Purdue Research Foundation (US) | 2026-02-11 | — | — | EP | claimed |
| CN-114450026-A | Sialic acid for use in the treatment of psoriasis | 生命科学股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| US-20220137053-A1 | LIPID BIOMARKERS FOR CANCER SCREENING AND MONITORING | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-05 | — | — | US | claimed |
| US-20220135678-A1 | METHODS AND COMPOSITIONS TO IMPROVE THE SAFETY AND EFFICACY OF CELLULAR THERAPIES | NATIONAL INSTITUTES OF HEALTH | 2022-05-05 | — | — | US | claimed |
| US-11307205-B2 | Non-radioactive cytotoxicity assays | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-04-19 | — | — | US | claimed |
| EP-3330279-B1 | METHOD FOR PURIFYING COMPOSITION COMPRISING ANTIBODIES WITH ANIONIC POLYMER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2022-04-06 | — | — | EP | claimed |
| EP-3972653-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | Massachusetts Institute of Technology (US) | 2022-03-30 | — | — | EP | claimed |
| US-20220090132-A1 | CAR T CELL METHODS AND CONSTRUCTS | ABINTUS BIO INC (US) | 2022-03-24 | — | — | US | claimed |
| WO-2022036041-A1 | IMPROVING IMMUNE CELL FUNCTION | KITE PHARMA, INC (US) | 2022-02-17 | — | — | WO | claimed |
| US-20220047677-A1 | IMMUNE CELL FUNCTION | KITE PHARMA, INC. | 2022-02-17 | — | — | US | claimed |
| WO-2022032293-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570711-B2 | Platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | NFRKB, NFATC1, NFKBIA | SIGLEC7 1202/4885SELP 557/4885MAG 2399/4885 |
| US-20260098074-A1 | IMMUNE CELL FUNCTION | IL15, IL15RA, ICOS | SIGLEC7 465/4885SELP 930/4885MAG 753/4885 |
| US-20260071235-A1 | METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO | CD4, HLA-DRB1, SARS1 | SIGLEC7 345/4885SELP 279/4885MAG 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.